Johnson & Johnson (JNJ) Other Non Operating Income (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Other Non Operating Income came in at -$331.0 million in Q2 2026, down 209.35% year-over-year from $302.7 million in Q2 2025, and down 12.59% quarter-over-quarter from -$294.0 million in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Other Non Operating Income (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Other Non Operating Income across 18 years of filings, most recently posting -$331.0 million for Q2 2026.
- In Q2 2026, Other Non Operating Income fell 209.35% year-over-year to -$331.0 million; the TTM figure through Jun 2026 stood at -$630.0 million (down 111.3% YoY), while the FY2025 annual figure was $7.2 billion, up 253.58% from the prior year.
- Other Non Operating Income came in at -$331.0 million for Q2 2026 at Johnson & Johnson, down from -$294.0 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $7.3 billion in Q1 2025 to a low of -$6.9 billion in Q2 2023.
- Average Other Non Operating Income over 5 years is -$303.9 million, with a median of -$283.5 million recorded in 2022.
- Year-over-year, Other Non Operating Income plunged 6903.92% in 2023 and soared 404.53% in 2025.
- Over 5 years, Other Non Operating Income stood at -$226.0 million in 2022, then surged by 286.28% to $421.0 million in 2023, then slumped by 61.76% to $161.0 million in 2024, then slumped by 400.0% to -$483.0 million in 2025, then soared by 31.47% to -$331.0 million in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were -$331.0 million in Q2 2026, -$294.0 million in Q1 2026, and -$483.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | -331.00 Mn |
| Mar 29, 2026 | -294.00 Mn |
| Dec 28, 2025 | -483.00 Mn |
| Sep 28, 2025 | 478.00 Mn |
| Jun 29, 2025 | -107.00 Mn |
| Mar 30, 2025 | 7.32 Bn |
| Dec 29, 2024 | 161.00 Mn |
| Sep 29, 2024 | -1.80 Bn |
| Jun 30, 2024 | -653.00 Mn |
| Mar 31, 2024 | -2.40 Bn |
| Dec 31, 2023 | 421.00 Mn |
| Oct 1, 2023 | -499.00 Mn |
| Jul 2, 2023 | 384.00 Mn |
| Apr 2, 2023 | -6.94 Bn |
| Jan 1, 2023 | -330.00 Mn |
| Oct 2, 2022 | -226.00 Mn |
| Jul 3, 2022 | -273.00 Mn |
| Apr 3, 2022 | 102.00 Mn |
| Oct 3, 2021 | -1.85 Bn |
| Jul 4, 2021 | 488.00 Mn |